Ask AI
ProCE Banner Activity

REZILIENT1: Zipalertinib in Patients With EGFR ex20ins–Mutated NSCLC After Prior Platinum-Based Chemotherapy ± Amivantamab

Conference Coverage
Slideset

The phase IIb REZILIENT1 trial showed promise with zipalertinib as a potential therapeutic option for EGFR ex20ins–mutated NSCLC in patients with progressive disease after platinum-based chemotherapy including those with or without previous exposure to amivantamab.

Released: June 09, 2025

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar